Allergic Rhinitis and Rhinoconjunctivitis
ROXALL Medizin GmbH focuses on moderate-to-severe allergic rhinitis and rhinoconjunctivitis linked to airborne allergens, with trials centered on symptom control and treatment tolerability in patients affected by seasonal and perennial disease patterns.
- House dust mite allergy
- Birch pollen allergy
- Grass pollen allergy
- Olive pollen allergy
The research portfolio includes both subcutaneous immunotherapy and sublingual immunotherapy approaches for upper-airway allergic disease.
Allergen Immunotherapy
The sponsor’s clinical activity is concentrated on allergen immunotherapy for respiratory allergy, with attention to treatment options designed to address specific sensitizations and improve allergic symptom burden.
- Cluster immunotherapy
- Sublingual immunotherapy
- Subcutaneous immunotherapy
- Allergen-specific treatment
Its studies examine multiple allergen sources, including pollen and mite-related triggers, across distinct therapeutic delivery routes.
Respiratory Allergy Symptom Management
Clinical research extends to outcomes relevant to day-to-day control of allergic symptoms, with emphasis on combined symptom and medication burden in patients with persistent respiratory allergy.
- Combined Symptom and Medication Score
- Benefit-risk balance
- Tolerability
- Allergic symptom relief
This area reflects interest in therapies for chronic nasal and ocular allergy manifestations associated with environmental exposure.
Seasonal and Perennial Aeroallergen Sensitization
The funded trials cover both seasonal allergic disease and perennial exposure-driven allergy, including sensitization to tree, grass, olive, and mite allergens.
- Tree pollen sensitization
- Grass pollen sensitization
- Olive pollen sensitization
- House dust mite sensitization
These studies address patient groups with sustained allergic symptoms over multiple years.
European Multicentre Allergy Research
The sponsor supports multicentre clinical research across Europe, with active trial sites in more than one country and a portfolio dedicated to allergic disease.
- Multicentre allergy trials
- Cross-country recruitment
- Respiratory allergen studies
- Specialist allergy sites
Its research activity is concentrated in patient populations with defined allergen-driven upper respiratory tract disease.
